Pharmacological evaluation of a novel 18F-benzamide with high uptake and specificity to melanotic tissues as a PET diagnostic agent for melanoma

With distinct increases in incidence and mortality of melanoma worldwide our objective was to prepare radiolabel and evaluate [18F]MEL054; an enticing novel melanin targeting PET radiopharmaceutical whose characteristics have been taken from our previously reported iodinated molecules [123I]MEL037 and [123I]MEL008. As the chemistry of [18F]MEL054 can be simply translated to an iodine based [131I]radiopharmaceutical this is our first phase in creating an effective diagnostic/therapeutic pair targeting metastatic melanoma. © Wiley

Keywords

Pharmacology, Fluorine 18, Neoplasms, Positron computed tomography, Labelling, Diagnostic techniques, Radiopharmaceuticals, Chemistry, Iodine, Tumor cells

Citation

Berghofer, P., Taylor, S. R., Ballantyne, P., Pham, T. Q., Loc’h, C., Wyatt, N., Nguyen, V. H., Denoyer, D., Hicks, R. J., Gregoire, M., Katsifis, A., & Greguric, I. (2013). Pharmacological evaluation of a novel 18F-benzamide with high uptake and specificity to melanotic tissues as a PET diagnostic agent for melanoma. Presentation to the 20th International Symposium on Radiopharmaceutical Sciences, 12-17 May 2013, Jeju, South Korea. In Journal of Labelled Compounds and Radiopharmaceuticals, 56(S1), S9. doi:10.1002/jlcr.3057